NORWOOD, MA—(Marketwired – March 02, 2018) – Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical–stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present at the Cowen & Co. 38th Annual Health Care Conference on Wednesday, March 14, 2018 at 8:40 a.m. EST in New York, NY.
Dr. Cohen will discuss the Company's four clinical development programs in diffuse cutaneous systemic sclerosis (“SSc”), cystic fibrosis (“CF”), skin–predominant dermatomyositis (“DM”) and systemic lupus erythematosus (“SLE”) for lenabasum, its novel, synthetic oral endocannabinoid–mimetic drug that is designed to resolve chronic inflammation and halt fibrosis.
Corbus' Phase 3 RESOLVE–1 study assessing the efficacy and safety of lenabasum for the treatment of SSc and its Phase 2 study of lenabasum for the treatment of SLE are currently underway. Additionally, the Company expects to initiate its next phase of development of lenabasum for the treatment of DM in the second half of 2018. Corbus recently announced the launch of its Phase 2b multicenter, double–blinded, randomized, placebo–controlled study of lenabasum for the treatment of CF that will enroll approximately 415 patients with CF who are at least 12 years of age and at increased risk for pulmonary exacerbations. In support of the Phase 2b study, Corbus received a Development Award for up to $25 million from the Cystic Fibrosis Foundation. The Company expects the first patient to be dosed in the Phase 2b CF study this quarter.
A live audio webcast of the presentation will be accessible on the Events page of the Investors section of Corbus website, www.corbuspharma.com, and will be archived on the Company's website for 90 days following the event.
Lenabasum (formerly known as anabasum) is a synthetic, oral, small–molecule, selective cannabinoid receptor type 2 (CB2) agonist that preferentially binds to CB2 expressed on activated immune cells and fibroblasts. CB2 activation triggers physiologic pathways that resolve inflammation, speed bacterial clearance and halt fibrosis. CB2 activation also induces the production of specialized pro–resolving lipid mediators that activate an endogenous cascade responsible for the resolution of inflammation and fibrosis, while reducing production of multiple inflammatory mediators. Through activation of CB2, lenabasum also is designed to have a direct effect on fibroblasts to halt tissue scarring. Lenabasum is believed to induce resolution rather than immunosuppression by triggering biological pathways to turn “off” chronic inflammation and fibrotic processes. Lenabasum has demonstrated promising potency in preclinical models of inflammation and fibrosis. Preclinical and human clinical studies have shown lenabasum to have a favorable safety, tolerability and pharmacokinetic profile. Further, the drug has demonstrated clinical benefit and positive impact on inflammatory and immunological markers in Phase 2 studies in diffuse cutaneous systemic sclerosis, dermatomyositis and cystic fibrosis.
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical–stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid–mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.
This press release contains certain forward–looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward–looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward–looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward–looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward–looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward–looking statement, whether as a result of new information, future events or otherwise.